Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Outsourcing
Lonza to sell finished dosage plants to NextPharma
by Rick Mullin
January 23, 2021
| A version of this story appeared in
Volume 99, Issue 3
Lonza will sell two plants that make liquid-filled hard capsules and softgel finished drugs to NextPharma, a drug services firm specializing in these areas. The plants in France and Scotland employ about 260 and 130 people, respectively. Lonza, which took on the operations when it bought Capsugel in 2016, intends to largely exit liquid-filled capsules and softgels for pharmaceuticals. It recently said it would invest about $96 million to expand its unfilled-capsule production by 30 billion per year.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter